Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB201 (Napabucasin) with Paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer
NCT03721744Phase 3Recruiting
- Sponsor
- 1Globe Health Institute
- Start
- Oct 2018
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of napabucasin in pancreatic adenocarcinoma (PDAC), sponsored by 1Globe Health Institute. Started Oct 2018; status: recruiting.
02
Drugs
napabucasin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03721744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03721744.